Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any familial cold autoinflammatory syndrome in which the cause of the disease is a mutation in the NLRC4 gene.
Features include: Urticaria, Arthralgia, and Fever.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 1 | Urticaria |
Bones and joints | 1 | Arthralgia |
Metabolism | 1 | Fever |
NLRC4 encodes NLR family CARD domain containing 4 (1,024 aa). Key component of inflammasomes that indirectly senses specific proteins from pathogenic bacteria and fungi and responds by assembling an inflammasome complex that promotes caspase-1 activation, cytokine production and macrophage pyroptosis. Highest expression in Whole Blood (25.8 TPM) and Spleen (13.8 TPM).
Familial cold autoinflammatory syndrome 4 is associated with mutations in the NLRC4 gene on chromosome 2.
The NLRC4 protein participates in TP53 stimulates NLRC4 expression, p-S15,S20-TP53:NLRC4 Gene, and TP53 Regulates Transcription of Caspase Activators and Caspases pathways.
NLRC4 is classified as a druggable target with score 0.0.
Genetic testing for NLRC4 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for familial cold autoinflammatory syndrome 4 has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for familial cold autoinflammatory syndrome 4.
26 publications have been identified in PubMed for familial cold autoinflammatory syndrome 4. Research spans Review / Meta-Analysis (27%), Epidemiology / Natural History (23%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 7 | 27% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 11:10 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Disease patterns and progression
6 |
23% |
Laboratory research | 4 | 15% |
Clinical study results | 3 | 12% |
Other research | 2 | 8% |
Patient case studies | 2 | 8% |
Testing and diagnosis research | 1 | 4% |
New treatment approaches | 1 | 4% |
Bouramtane A (2026). [PMID: 41261519](https://pubmed.ncbi.nlm.nih.gov/41261519/). *Int J Immunogenet*. [Review / Meta-Analysis]
Kato C (2026). [PMID: 41263512](https://pubmed.ncbi.nlm.nih.gov/41263512/). *Mod Rheumatol*. [Epidemiology / Natural History]
Snouwaert JN (2026). [PMID: 41797712](https://pubmed.ncbi.nlm.nih.gov/41797712/). *JCI Insight*. [Basic Science / Preclinical]
Chu H (2026). [PMID: 41086530](https://pubmed.ncbi.nlm.nih.gov/41086530/). *Eur J Med Chem*. [Gene Therapy / Novel Therapeutics]
Levin JA (2026). [PMID: 41961992](https://pubmed.ncbi.nlm.nih.gov/41961992/). *A A Pract*. [Case Report / Case Series]
Koller BH (2026). [PMID: 41723527](https://pubmed.ncbi.nlm.nih.gov/41723527/). *J Neuroinflammation*. [Basic Science / Preclinical]
Quach A (2025). [PMID: 39891630](https://pubmed.ncbi.nlm.nih.gov/39891630/). *J Allergy Clin Immunol*. [Other]
Melo Gomes S (2025). [PMID: 40538939](https://pubmed.ncbi.nlm.nih.gov/40538939/). *Front Pediatr*. [Epidemiology / Natural History]
Hou C (2025). [PMID: 40194758](https://pubmed.ncbi.nlm.nih.gov/40194758/). *Joint Bone Spine*. [Review / Meta-Analysis]
Tsai CK (2025). [PMID: 40234085](https://pubmed.ncbi.nlm.nih.gov/40234085/). *Open Heart*. [Other]